{"contraindications":{"vaccineGroup":{"contraindication":[{"observationCode":"007","observationTitle":"Pregnant","contraindicationText":"Do not vaccinate if the patient is pregnant."},{"observationCode":"080","observationTitle":"Adverse reaction to vaccine component","contraindicationText":"Do not vaccinate if the patient has had an adverse reaction to a vaccine component."},{"observationCode":"090","observationTitle":"Severe allergic reaction after previous dose of HPV","contraindicationText":"Do not vaccinate if the patient has had a severe allergic reaction after a previous dose of HPV vaccine."},{"observationCode":"110","observationTitle":"Hypersensitivity to yeast","contraindicationText":"Do not vaccinate with 9vHPV if the patient has a hypersensitivity to yeast."}]}},"series":[{"seriesName":"HPV 2-dose series","targetDisease":"HPV","vaccineGroup":"HPV","seriesType":"Standard","equivalentSeriesGroups":"2","requiredGender":["Female","Transgender","Unknown"],"selectSeries":{"defaultSeries":"Yes","productPath":"No","seriesGroupName":"Standard","seriesGroup":"1","seriesPriority":"A","seriesPreference":"1","maxAgeToStart":"15 years"}},{"seriesName":"HPV 3-dose series","targetDisease":"HPV","vaccineGroup":"HPV","seriesType":"Standard","equivalentSeriesGroups":"2","requiredGender":["Female","Transgender","Unknown"],"selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Standard","seriesGroup":"1","seriesPriority":"A","seriesPreference":"2","minAgeToStart":"15 years"}},{"seriesName":"HPV male 2-dose series","targetDisease":"HPV","vaccineGroup":"HPV","seriesType":"Standard","equivalentSeriesGroups":"2","requiredGender":["Male"],"selectSeries":{"defaultSeries":"Yes","productPath":"No","seriesGroupName":"Standard","seriesGroup":"1","seriesPriority":"A","seriesPreference":"1","maxAgeToStart":"15 years"}},{"seriesName":"HPV male 3-dose series","targetDisease":"HPV","vaccineGroup":"HPV","seriesType":"Standard","equivalentSeriesGroups":"2","requiredGender":["Male"],"selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Standard","seriesGroup":"1","seriesPriority":"A","seriesPreference":"2","minAgeToStart":"15 years"}},{"seriesName":"HPV risk 2-dose series","targetDisease":"HPV","vaccineGroup":"HPV","seriesType":"Risk","equivalentSeriesGroups":"1","requiredGender":["Female","Transgender","Unknown"],"selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"A","seriesPreference":"1","minAgeToStart":"0 days","maxAgeToStart":"11 years"},"indication":[{"observationCode":{"text":"History of sexual abuse or assault","code":"169"},"description":"Administer to persons who have a history of sexual abuse or assault.","beginAge":"0 days","endAge":"11 years"}]},{"seriesName":"HPV risk male 2-dose series","targetDisease":"HPV","vaccineGroup":"HPV","seriesType":"Risk","equivalentSeriesGroups":"1","requiredGender":["Male"],"selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"A","seriesPreference":"1","minAgeToStart":"0 days","maxAgeToStart":"11 years"},"indication":[{"observationCode":{"text":"History of sexual abuse or assault","code":"169"},"description":"Administer to persons who have a history of sexual abuse or assault.","beginAge":"0 days","endAge":"11 years"}]},{"seriesName":"HPV risk 3-dose series","targetDisease":"HPV","vaccineGroup":"HPV","seriesAdminGuidance":["At the provider's discretion, the recommendation for a 3-dose schedule does not apply to children aged less than 15 years with asplenia, asthma, chronic granulomatous disease, chronic liver disease, chronic lung disease, chronic renal disease, CNS anatomic barrier defines (e.g., cochlear implant), complement deficiency, diabetes, heart disease, or sickle cell disease."],"seriesType":"Risk","equivalentSeriesGroups":"1","requiredGender":["Female","Transgender","Unknown"],"selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"A","seriesPreference":"1","minAgeToStart":"9 years","maxAgeToStart":"27 years"},"indication":[{"observationCode":{"text":"B-lymphocyte [humoral] - Severe antibody deficiencies","code":"145"},"description":"Administer to persons who have severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).","beginAge":"9 years"},{"observationCode":{"text":"B-lymphocyte [humoral] - Less severe antibody deficiencies","code":"146"},"description":"Administer to persons who have less severe B-lymphocyte (humoral) - antibody deficiencies (e.g., selective IgA deficiency and IgG subclass deficiency).","beginAge":"9 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - Complete defects","code":"147"},"description":"Administer to persons who have complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).","beginAge":"9 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - Partial defects","code":"148"},"description":"Administer to persons who have partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).","beginAge":"9 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - interferon-gamma/Interleukin 12 axis deficiencies","code":"149"},"description":"Administer to persons who have T-lymphocyte [cell-mediated and humoral] - interferon-gamma/Interleukin 12 axis deficiencies.","beginAge":"9 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - interferon-gamma or interferon-alpha","code":"150"},"description":"Administer to persons who have T-lymphocyte [cell-mediated and humoral] - interferon-gamma or interferon-alpha.","beginAge":"9 years"},{"observationCode":{"text":"Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency","code":"153"},"description":"Administer to persons who have a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).","beginAge":"9 years"},{"observationCode":{"text":"Generalized malignant neoplasm","code":"156"},"description":"Administer to persons who have generalized malignant neoplasm.","beginAge":"9 years"},{"observationCode":{"text":"Transplantation","code":"157"},"description":"Administer to persons who have received a transplant.","beginAge":"9 years"},{"observationCode":{"text":"Immunosuppressive therapy","code":"158"},"description":"Administer to persons who are undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. ","beginAge":"9 years"},{"observationCode":{"text":"Radiation therapy","code":"159"},"description":"Administer to persons who are undergoing radiation therapy.","beginAge":"9 years"},{"observationCode":{"text":"HIV Infection"},"description":"Administer to persons with HIV Infection","beginAge":"9 years"}]},{"seriesName":"HPV risk male 3-dose series","targetDisease":"HPV","vaccineGroup":"HPV","seriesAdminGuidance":["At the provider's discretion, the recommendation for a 3-dose schedule does not apply to children aged less than 15 years with asplenia, asthma, chronic granulomatous disease, chronic liver disease, chronic lung disease, chronic renal disease, CNS anatomic barrier defines (e.g., cochlear implant), complement deficiency, diabetes, heart disease, or sickle cell disease."],"seriesType":"Risk","equivalentSeriesGroups":"1","requiredGender":["Male"],"selectSeries":{"defaultSeries":"No","productPath":"No","seriesGroupName":"Increased Risk","seriesGroup":"2","seriesPriority":"A","seriesPreference":"1","minAgeToStart":"9 years","maxAgeToStart":"27 years"},"indication":[{"observationCode":{"text":"B-lymphocyte [humoral] - Severe antibody deficiencies","code":"145"},"description":"Administer to persons who have severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).","beginAge":"9 years"},{"observationCode":{"text":"B-lymphocyte [humoral] - Less severe antibody deficiencies","code":"146"},"description":"Administer to persons who have less severe B-lymphocyte (humoral) - antibody deficiencies (e.g., selective IgA deficiency and IgG subclass deficiency).","beginAge":"9 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - Complete defects","code":"147"},"description":"Administer to persons who have complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).","beginAge":"9 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - Partial defects","code":"148"},"description":"Administer to persons who have partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).","beginAge":"9 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - interferon-gamma/Interleukin 12 axis deficiencies","code":"149"},"description":"Administer to persons who have T-lymphocyte [cell-mediated and humoral] - interferon-gamma/Interleukin 12 axis deficiencies.","beginAge":"9 years"},{"observationCode":{"text":"T-lymphocyte [cell-mediated and humoral] - interferon-gamma or interferon-alpha","code":"150"},"description":"Administer to persons who have T-lymphocyte [cell-mediated and humoral] - interferon-gamma or interferon-alpha.","beginAge":"9 years"},{"observationCode":{"text":"Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency","code":"153"},"description":"Administer to persons who have a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).","beginAge":"9 years"},{"observationCode":{"text":"Generalized malignant neoplasm","code":"156"},"description":"Administer to persons who have generalized malignant neoplasm.","beginAge":"9 years"},{"observationCode":{"text":"Transplantation","code":"157"},"description":"Administer to persons who have received a transplant.","beginAge":"9 years"},{"observationCode":{"text":"Immunosuppressive therapy","code":"158"},"description":"Administer to persons who are undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. ","beginAge":"9 years"},{"observationCode":{"text":"Radiation therapy","code":"159"},"description":"Administer to persons who are undergoing radiation therapy.","beginAge":"9 years"},{"observationCode":{"text":"HIV Infection"},"description":"Administer to persons with HIV Infection","beginAge":"9 years"}]}]}